Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers

Yuqian Bao, Tie Zhao, Xiaoyan Wang, Yunping Qiu, Mingming Su, Wei Jia, Weiping Jia

Research output: Contribution to journalArticle

93 Citations (Scopus)

Abstract

The pathological development and the drug intervention of type 2 diabetes mellitus (T2DM) involve altered expression of downstream low molecular weight metabolites including lipids and amino acids, and carbohydrates such as glucose. Currently, a small number of markers used for clinical assessment of T2DM treatment may be insufficient to reflect global variations in pathophysiology. In this study, a metabonomic study was performed to determine metabolic variations associated with T2DM and the drug treatments on 74 patients who were newly diagnosed with T2DM and received a 48 week treatment of a single drug, repaglinide, metformin or rosiglitazone. Fasting overnight and 2 h postprandial blood serum of patients were collected at 24 and 48 weeks to monitor the biochemical indices (FPG, 2hPG, HbA 1c, etc.). Gas chromatography/mass spectrometer coupled with multivariate statistical analysis was used to identify the alteration of global serum metabolites associated with T2DM as compared to healthy controls and responses to drug treatment. Significantly altered serum metabolites in diabetic subjects include increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. All of the three treatments were able to down-regulate the high level of glutamate to a lower level in serum of T2DM patients, but rosiglitazone treatment was able to reverse more abnormal levels of metabolites, such as valine, lysine, glucuronolactone, C16:0, C18:1, urate, and octadecanoate, suggesting that it is more efficient to alter the metabolism of T2DM patients than the other two drugs.

Original languageEnglish (US)
Pages (from-to)1623-1630
Number of pages8
JournalJournal of Proteome Research
Volume8
Issue number4
DOIs
StatePublished - Apr 3 2009
Externally publishedYes

Fingerprint

Metabolomics
Medical problems
Type 2 Diabetes Mellitus
Healthy Volunteers
rosiglitazone
Metabolites
Pharmaceutical Preparations
Drug therapy
Stearates
repaglinide
Valine
Uric Acid
Serum
Lysine
Glutamic Acid
Therapeutics
Maltose
Metformin
Mass spectrometers
Metabolism

Keywords

  • Gas chromatography/mass spectrometry
  • metabonomics
  • Metformin
  • Repaglinide
  • Rosiglitazone
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Biochemistry
  • Chemistry(all)

Cite this

Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers. / Bao, Yuqian; Zhao, Tie; Wang, Xiaoyan; Qiu, Yunping; Su, Mingming; Jia, Wei; Jia, Weiping.

In: Journal of Proteome Research, Vol. 8, No. 4, 03.04.2009, p. 1623-1630.

Research output: Contribution to journalArticle

Bao, Yuqian ; Zhao, Tie ; Wang, Xiaoyan ; Qiu, Yunping ; Su, Mingming ; Jia, Wei ; Jia, Weiping. / Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers. In: Journal of Proteome Research. 2009 ; Vol. 8, No. 4. pp. 1623-1630.
@article{0f63a1eaf8bd44a4b6961b7932e8a7c7,
title = "Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers",
abstract = "The pathological development and the drug intervention of type 2 diabetes mellitus (T2DM) involve altered expression of downstream low molecular weight metabolites including lipids and amino acids, and carbohydrates such as glucose. Currently, a small number of markers used for clinical assessment of T2DM treatment may be insufficient to reflect global variations in pathophysiology. In this study, a metabonomic study was performed to determine metabolic variations associated with T2DM and the drug treatments on 74 patients who were newly diagnosed with T2DM and received a 48 week treatment of a single drug, repaglinide, metformin or rosiglitazone. Fasting overnight and 2 h postprandial blood serum of patients were collected at 24 and 48 weeks to monitor the biochemical indices (FPG, 2hPG, HbA 1c, etc.). Gas chromatography/mass spectrometer coupled with multivariate statistical analysis was used to identify the alteration of global serum metabolites associated with T2DM as compared to healthy controls and responses to drug treatment. Significantly altered serum metabolites in diabetic subjects include increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. All of the three treatments were able to down-regulate the high level of glutamate to a lower level in serum of T2DM patients, but rosiglitazone treatment was able to reverse more abnormal levels of metabolites, such as valine, lysine, glucuronolactone, C16:0, C18:1, urate, and octadecanoate, suggesting that it is more efficient to alter the metabolism of T2DM patients than the other two drugs.",
keywords = "Gas chromatography/mass spectrometry, metabonomics, Metformin, Repaglinide, Rosiglitazone, Type 2 diabetes mellitus",
author = "Yuqian Bao and Tie Zhao and Xiaoyan Wang and Yunping Qiu and Mingming Su and Wei Jia and Weiping Jia",
year = "2009",
month = "4",
day = "3",
doi = "10.1021/pr800643w",
language = "English (US)",
volume = "8",
pages = "1623--1630",
journal = "Journal of Proteome Research",
issn = "1535-3893",
publisher = "American Chemical Society",
number = "4",

}

TY - JOUR

T1 - Metabonomic variations in the drug-treated type 2 diabetes mellitus patients and healthy volunteers

AU - Bao, Yuqian

AU - Zhao, Tie

AU - Wang, Xiaoyan

AU - Qiu, Yunping

AU - Su, Mingming

AU - Jia, Wei

AU - Jia, Weiping

PY - 2009/4/3

Y1 - 2009/4/3

N2 - The pathological development and the drug intervention of type 2 diabetes mellitus (T2DM) involve altered expression of downstream low molecular weight metabolites including lipids and amino acids, and carbohydrates such as glucose. Currently, a small number of markers used for clinical assessment of T2DM treatment may be insufficient to reflect global variations in pathophysiology. In this study, a metabonomic study was performed to determine metabolic variations associated with T2DM and the drug treatments on 74 patients who were newly diagnosed with T2DM and received a 48 week treatment of a single drug, repaglinide, metformin or rosiglitazone. Fasting overnight and 2 h postprandial blood serum of patients were collected at 24 and 48 weeks to monitor the biochemical indices (FPG, 2hPG, HbA 1c, etc.). Gas chromatography/mass spectrometer coupled with multivariate statistical analysis was used to identify the alteration of global serum metabolites associated with T2DM as compared to healthy controls and responses to drug treatment. Significantly altered serum metabolites in diabetic subjects include increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. All of the three treatments were able to down-regulate the high level of glutamate to a lower level in serum of T2DM patients, but rosiglitazone treatment was able to reverse more abnormal levels of metabolites, such as valine, lysine, glucuronolactone, C16:0, C18:1, urate, and octadecanoate, suggesting that it is more efficient to alter the metabolism of T2DM patients than the other two drugs.

AB - The pathological development and the drug intervention of type 2 diabetes mellitus (T2DM) involve altered expression of downstream low molecular weight metabolites including lipids and amino acids, and carbohydrates such as glucose. Currently, a small number of markers used for clinical assessment of T2DM treatment may be insufficient to reflect global variations in pathophysiology. In this study, a metabonomic study was performed to determine metabolic variations associated with T2DM and the drug treatments on 74 patients who were newly diagnosed with T2DM and received a 48 week treatment of a single drug, repaglinide, metformin or rosiglitazone. Fasting overnight and 2 h postprandial blood serum of patients were collected at 24 and 48 weeks to monitor the biochemical indices (FPG, 2hPG, HbA 1c, etc.). Gas chromatography/mass spectrometer coupled with multivariate statistical analysis was used to identify the alteration of global serum metabolites associated with T2DM as compared to healthy controls and responses to drug treatment. Significantly altered serum metabolites in diabetic subjects include increased valine, maltose, glutamate, urate, butanoate and long-chain fatty acid (C16:0, C18:1, C18:0, octadecanoate and arachidonate), and decreased glucuronolactone, lysine and lactate. All of the three treatments were able to down-regulate the high level of glutamate to a lower level in serum of T2DM patients, but rosiglitazone treatment was able to reverse more abnormal levels of metabolites, such as valine, lysine, glucuronolactone, C16:0, C18:1, urate, and octadecanoate, suggesting that it is more efficient to alter the metabolism of T2DM patients than the other two drugs.

KW - Gas chromatography/mass spectrometry

KW - metabonomics

KW - Metformin

KW - Repaglinide

KW - Rosiglitazone

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=65249113837&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=65249113837&partnerID=8YFLogxK

U2 - 10.1021/pr800643w

DO - 10.1021/pr800643w

M3 - Article

C2 - 19714868

AN - SCOPUS:65249113837

VL - 8

SP - 1623

EP - 1630

JO - Journal of Proteome Research

JF - Journal of Proteome Research

SN - 1535-3893

IS - 4

ER -